Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AbbVie Inc. (ABBV)

135.87   2.35 (1.76%) 01-16 05:09
Open: 133.35 Pre. Close: 133.52
High: 136.05 Low: 132.2906
Volume: 10,374,310 Market Cap: 240,202M
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 136.204 - 136.745 136.745 - 137.211
Low: 130.804 - 131.467 131.467 - 132.039
Close: 134.711 - 135.806 135.806 - 136.749

Technical analysis

as of: 2022-01-15 8:44:05 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 161.36     One year: 188.47
Support: Support1: 129.23    Support2: 123.72
Resistance: Resistance1: 138.15    Resistance2: 161.36
Pivot: 135.47
Moving Average: MA(5): 136.01     MA(20): 134.38
MA(100): 117.90     MA(250): 114.19
MACD: MACD(12,26): 3.03     Signal(9): 3.60
Stochastic oscillator: %K(14,3): 57.80     %D(3): 70.16
RSI: RSI(14): 63.43
52-week: High: 138.15  Low: 101.81  Change(%): 22.1
Average Vol(K): 3-Month: 639982  10-Days: 765719

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
ABBV has closed below upper band by 39.6%. Bollinger Bands are 61.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to ABBV's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 14 Jan 2022
AbbVie Inc (ABBV) has fallen -1.48% in a Week, Should You Sell? - InvestorsObserver

Tue, 11 Jan 2022
AbbVie Inc. (ABBV) Management Presents at JPMorgan 40th Annual Healthcare Conference (Transcript) - Seeking Alpha

Mon, 10 Jan 2022
AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS - Entrepreneur

Sat, 08 Jan 2022
Just Four Days Till AbbVie Inc. (NYSE:ABBV) Will Be Trading Ex-Dividend - Nasdaq

Fri, 07 Jan 2022
Zacks Investment Ideas feature highlights: AbbVie, Inc. and Pfizer Inc - Yahoo Finance

Thu, 06 Jan 2022
AbbVie: Doing The RIG(HT) Thing - Seeking Alpha

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. (M) 1,770
Shares Float (M) 1,750
% Held by Insiders 0.12
% Held by Institutions 68.22
Shares Short (K) 16,610
Shares Short P. Month (K) 14,120

Stock Financials

EPS 4.200
EPS Est This Year 5.530
EPS Est Next Year 6.560
Book Value (p.s.) 7.660
Profit Margin 13.66
Operating Margin 36.70
Return on Assets (ttm) 8.5
Return on Equity (ttm) 52.3
Qtrly Rev. Growth 11.2
Gross Profit (p.s.) 17.938
Sales Per Share 31.169
EBITDA (p.s.) 16.299
Qtrly Earnings Growth 37.70
Operating Cash Flow (M) 22,560
Levered Free Cash Flow (M) 20,340

Stock Valuations

PE Ratio 32.35
PEG Ratio
Price to Book value 17.74
Price to Sales 4.36
Price to Cash Flow 10.66

Stock Dividends

Dividend 5.200
Forward Dividend 5.640
Dividend Yield 0.04
Dividend Pay Date 2022-02-14
Ex-Dividend Date 2022-01-12
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.